Volume 23, Issue 3 pp. 248-252
Original Article

Efficacy of Plasma Exchange in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Keisuke Nishimura

Corresponding Author

Keisuke Nishimura

Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan

Address correspondence and reprint requests to Dr Keisuke Nishimura, Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, 1-1-1, Miwa, Kurashiki, 710-8602, Japan. Email: [email protected]Search for more papers by this author
Daisuke Waki

Daisuke Waki

Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan

Search for more papers by this author
Keiichiro Kadoba

Keiichiro Kadoba

Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan

Search for more papers by this author
Hiroki Mukoyama

Hiroki Mukoyama

Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan

Search for more papers by this author
Toshihiko Yokota

Toshihiko Yokota

Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan

Search for more papers by this author
Hiroyuki Murabe

Hiroyuki Murabe

Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan

Search for more papers by this author
First published: 29 April 2019
Citations: 3
Presented in part at the 39th Congress of the Japanese Society for Apheresis held October 25–27, 2018 in Okayama Prefecture, Japan.

Abstract

We aimed to investigate the efficacy of plasma exchange on severe anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Of 182 patients with AAV in our hospital, 12 patients with life-threatening organ damage (rapidly progressive glomerulonephritis and/or diffuse alveolar hemorrhage) underwent centrifuge-based therapeutic plasma exchange and immunosuppressive therapy. Twenty-four patients matched for age, serum creatinine, and severity of vasculitis, who received high-dose glucocorticoids with or without immunosuppressants, were included in the nonplasma exchange group. Renal survival rate at 2 years from induction treatment was not significantly different between the plasma and nonplasma exchange groups (P = 0.524). Mortality rate at 5 years from induction treatment was not significantly different between the plasma and nonplasma exchange groups (P = 0.631). In this retrospective study, we could not show the significant differences in the renal survival rate and survival rate between the two groups.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.